Clinical Trial Finds Pelacarsen Lowers Lipoprotein(a) Without Reducing Cardiovascular Events
A major international trial revealed that while the monthly injection pelacarsen successfully reduces lipoprotein(a) levels, it does not decrease major adverse cardiovascular events in adults with existing heart disease.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- Pelacarsen reduced lipoprotein(a) levels by roughly 78 percent at 12 months.
- The international trial followed over 8,300 patients with preexisting heart disease for a median of 4.7 years.
- Major adverse cardiovascular events occurred at similar rates between the treatment and placebo groups.
An investigational therapy known as pelacarsen successfully reduced lipoprotein(a) levels in adults with preexisting cardiovascular disease, but failed to lower the overall incidence of major adverse cardiovascular events, according to a study published in the New England Journal of Medicine. The findings were simultaneously presented at the American Heart Association Scientific Sessions in Chicago.
Led by Dr. Leslie Cho and senior author Dr. Steven E. Nissen from the Cleveland Clinic, the international, randomized, placebo-controlled trial followed 8,322 participants over a median of 4.7 years. Patients received either monthly subcutaneous injections of pelacarsen or a placebo. Baseline median lipoprotein(a) levels stood at 236 nmol/L. After one year, the treatment group achieved a dramatic 78 percent reduction, bringing median levels down to 64.4 nmol/L compared to 233.4 nmol/L in the placebo group.
Despite successfully lowering the biomarker, primary endpoint events occurred in 12.3 percent of patients receiving pelacarsen and 12.1 percent of those taking the placebo. Dr. Nissen noted in a statement that the neutral outcome was unexpected and surprising to the medical community. The study also observed serious adverse events in 37.3 percent of the pelacarsen cohort and 41.1 percent of the placebo group.
What to know: While biomarker reduction is often used as a surrogate marker for lower cardiovascular risk, this trial demonstrates that lowering lipoprotein(a) via pelacarsen does not automatically translate to fewer cardiac events in this patient population. Readers should consult a qualified healthcare provider for personalized medical decisions regarding heart health management.
Source Medical Xpress — medicalxpress.com/news/2026-11-aha-pelacarsen-lipoproteina-major-advers… ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …